DOSAGE / RESEARCH CONTEXT
GHK-Cu Dosage as Studied: Routes, Concentrations and the PK Gap
What was administered, to which model, by which route — and where the human pharmacokinetic record is simply empty.
How GHK-Cu dosage appears in the studies
GHK-Cu dosage in the research literature is reported as study concentrations and animal protocols, not as a human regimen. There is no approved therapeutic dose for GHK-Cu by any systemic route. What follows describes what investigators administered, to which model, by which route — strictly as documented.
In vitro, dermal fibroblast collagen synthesis was driven across 10^-12 to 10^-9 M, with onset between 10^-12 and 10^-11 M and a peak near 10^-9 M [1]. That is a picomolar-to-nanomolar window — the effect appears at concentrations far below what a topical product delivers, which is part of why the delivery question matters more than raw concentration. Topical cosmetic and clinical formulations sit at approximately 0.05% to 2% (w/w) in creams, serums and gels [3], and the human hair-loss trial used an ALAVAX 5-ALA + GHK topical at 50-100 mg/mL [4]. The numbers are not interchangeable: a molar in-vitro figure, a weight-percent cosmetic figure and a milligram-per-millilitre trial figure describe different things and cannot be read off against one another.
Routes studied and rodent protocols
GHK and GHK-Cu have been administered by a wide range of routes in research: topical (cream, serum, liposome, nano-lipid carrier, ionic-liquid microemulsion, wound dressing, nanofiber), intraperitoneal in rodent systemic studies, intranasal in rodent cognition studies, oral gavage in rodent colitis, intravenous or subcutaneous in pharmacokinetic studies, and intradermal or microneedle delivery in hair studies [3].
The rodent systemic literature reports specific, model-bound protocols. Pulmonary emphysema studies dosed intraperitoneally at 0.2, 2 and 20 ug/g/day on alternate days; pulmonary fibrosis at 2.6, 26 and 260 ug/mL/day; silicosis at 2 and 20 mg/kg; and a DSS-colitis model at 20 mg/kg by daily oral gavage [3]. Aging and cognition studies used the intranasal route at 15 mg/kg, daily or three times weekly, and behavioral studies dosed intraperitoneally across roughly 0.5 ug/kg to 0.5 mg/kg [3]. The 2024 hair study used a topical 2% GHK-Cu ionic-liquid microemulsion on mouse scalp [14].
The spread of those numbers is the point: dose, route and species change with every model, and none of them maps to a human regimen. Reassuringly, the rodent studies used copper loads below the approximately 35 mg/kg ion-toxicity threshold [3]. This digest reports each protocol as it was published and does not convert any of them into a human dose.
Half-life and the dermal copper depot
No rigorous human pharmacokinetic half-life has been published for GHK-Cu [3]. The free tripeptide (340.38 Da) is rapidly cleared by plasma peptidases: a rat HPLC study documented rapid metabolism of GHK to the dipeptide histidyl-lysine after intravenous dosing (detection limits 50 ng/mL GHK, 15 ng/mL HK) [10]. Secondary literature cites a short systemic elimination half-life on the order of 1-2 hours, with the copper-chelated complex more stable than free GHK [3].
Topical application behaves differently. It forms a dermal copper depot — about 97 +/- 6.6 ug/cm^2 of copper retained over 48 hours in human skin [5] — giving prolonged local availability that a plasma half-life does not capture. The complex's high copper stability constant (log K approximately 16.4) is what keeps free-copper release low through that window [3].
Is GHK-Cu safe for long-term use?
Topical copper-tripeptide cosmetics have a long marketed safety record, but there are no long-term human safety trials of systemic GHK-Cu [3]. The complex's high copper stability constant (log K approximately 16.4) limits free-copper release [3]; a theoretical copper-accumulation risk with prolonged systemic use is noted in the literature, with no human copper-toxicity cases attributed to GHK-Cu in the peer-reviewed record [3].
What the human clinical record actually covers
Human evidence for GHK-Cu is predominantly topical and dermatologic. It consists of small placebo-controlled facial cream and serum trials (n approximately 20-71) reporting improved skin density, firmness, fine lines and wrinkle depth, plus the 6-month, 45-patient hair-loss trial of an ALAVAX 5-ALA + GHK complex showing significant hair-count gains versus placebo [3][4]. A topical wound-healing trial (CuHeal, NCT07437586) has been registered [3].
What the record does not contain is just as important. There are no completed Phase 2/3 trials for systemic or injectable GHK-Cu, and no validated human pharmacokinetic data — no measured half-life, Cmax, bioavailability or tissue distribution — for those routes [3]. Injectable and systemic dosing protocols that circulate in community contexts have no peer-reviewed pharmacokinetic basis [3]. We document the topical and dermatologic studies that exist; we do not reproduce community protocols, because there is no published human data to anchor them.
One regulatory note for completeness: GHK-Cu is not currently listed on the WADA Prohibited List as of the 2024-2025 lists, distinct from some other research peptides, though WADA's catch-all S0 category can cover non-approved pharmacological substances [3]. Any athletic-research context should verify the current Prohibited List directly.